Certolizumab doesn’t cross the placenta


The continuation of the anti-TNF certolizumab during pregnancy may be an option for women who need their disease activity controlled because it doesn’t cross the placenta in significant concentrations, a pharmacokinetic study shows. Presenting their findings at EULAR the authors led by Professor Xavier Mariette from the University Hospitals of Paris-Sud, France, said they expected ...


Already a member? Login to keep reading


OR
© 2017 the limbic